| Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers HM Dunnenberger, KR Crews, JM Hoffman, KE Caudle, U Broeckel, ... Annual review of pharmacology and toxicology 55, 89-106, 2015 | 297 | 2015 |
| Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process K E Caudle, T E Klein, J M Hoffman, D J Muller, M Whirl-Carrillo, L Gong, ... Current drug metabolism 15 (2), 209-217, 2014 | 283 | 2014 |
| Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) KE Caudle, HM Dunnenberger, RR Freimuth, JF Peterson, JD Burlison, ... Genetics in Medicine 19 (2), 215-223, 2017 | 261 | 2017 |
| Economic evaluations of clinical pharmacy services: 2001–2005 F Doloresco, JM Hoffman, PD Meek Pharmacotherapy 28 (11), 285e-323e, 2008 | 200 | 2008 |
| Development and use of active clinical decision support for preemptive pharmacogenomics GC Bell, KR Crews, MR Wilkinson, CE Haidar, JK Hicks, DK Baker, ... Journal of the American Medical Informatics Association 21 (e1), e93-e99, 2014 | 177 | 2014 |
| PG4KDS: a model for the clinical implementation of pre‐emptive pharmacogenetics JM Hoffman, CE Haidar, MR Wilkinson, KR Crews, DK Baker, ... American Journal of Medical Genetics Part C: Seminars in Medical Genetics …, 2014 | 171 | 2014 |
| NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives AD Zelenetz, I Ahmed, EL Braud, JD Cross, N Davenport-Ennis, ... Journal of the National Comprehensive Cancer Network 9 (Suppl_4), S-1-S-22, 2011 | 171 | 2011 |
| Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza AH Gaur, B Bagga, S Barman, R Hayden, A Lamptey, JM Hoffman, ... New England journal of medicine 362 (1), 88-89, 2010 | 168 | 2010 |
| Development and implementation of a pharmacist-managed clinical pharmacogenetics service KR Crews, SJ Cross, JN McCormick, DK Baker, AR Molinelli, R Mullins, ... American Journal of Health-System Pharmacy 68 (2), 143-150, 2011 | 136 | 2011 |
| Economic evaluations of clinical pharmacy services: 2006–2010 DR Touchette, F Doloresco, KJ Suda, A Perez, S Turner, Y Jalundhwala, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34 (8 …, 2014 | 127 | 2014 |
| Medication errors caused by confusion of drug names JM Hoffman, SM Proulx Drug safety 26 (7), 445-452, 2003 | 125 | 2003 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update MA Martin, JM Hoffman, RR Freimuth, TE Klein, BJ Dong, M Pirmohamed, ... Clinical Pharmacology & Therapeutics 95 (5), 499-500, 2014 | 107 | 2014 |
| National survey on the effect of oncology drug shortages on cancer care A McBride, LM Holle, C Westendorf, M Sidebottom, N Griffith, RJ Muller, ... American journal of health-system pharmacy 70 (7), 609-617, 2013 | 98 | 2013 |
| A clinician‐driven automated system for integration of pharmacogenetic interpretations into an electronic medical record JK Hicks, KR Crews, JM Hoffman, NM Kornegay, MR Wilkinson, R Lorier, ... Clinical Pharmacology & Therapeutics 92 (5), 563-566, 2012 | 94 | 2012 |
| The second victim experience and support tool (SVEST): validation of an organizational resource for assessing second victim effects and the quality of support resources JD Burlison, SD Scott, EK Browne, SG Thompson, JM Hoffman Journal of patient safety 13 (2), 93, 2017 | 84 | 2017 |
| Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC) JM Hoffman, HM Dunnenberger, J Kevin Hicks, KE Caudle, ... Journal of the American Medical Informatics Association 23 (4), 796-801, 2016 | 73 | 2016 |
| ASHP guidelines on preventing medication errors with chemotherapy and biotherapy B Goldspiel, JM Hoffman, NL Griffith, S Goodin, R DeChristoforo, ... American Journal of Health-System Pharmacy 72 (8), e6-e35, 2015 | 70 | 2015 |
| Patient safety culture and the second victim phenomenon: connecting culture to staff distress in nurses RR Quillivan, JD Burlison, EK Browne, SD Scott, JM Hoffman The Joint Commission Journal on Quality and Patient Safety 42 (8), 377-AP2, 2016 | 69 | 2016 |
| Biosimilars: implications for health-system pharmacists SD Lucio, JG Stevenson, JM Hoffman American journal of health-system pharmacy 70 (22), 2004-2017, 2013 | 69 | 2013 |
| Projecting future drug expenditures—2012 JM Hoffman, E Li, F Doloresco, L Matusiak, RJ Hunkler, ND Shah, ... American Journal of Health-System Pharmacy 69 (5), 405-421, 2012 | 69 | 2012 |
Mary V. RellingSt. Jude Children's Research HospitalVerified email at stjude.org
